Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
India has the second-largest number of adults with diabetes globally, after China
The pharma companies will bring quality products at competitive prices to consumers in Oman and help bring down the cost of healthcare
The licences will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries
As part of the celebrations, the Institute organised a series of activities in the run up to International Nurses Day which is observed on 12th May every year
Candle Partners, an investment banking & advisory service for M&A among others, has closed many deals in the healthcare space. Ankit Poddar, Director, Candle Partners spoke to Thomas C Thottathil, Editor, Indianpharmapost.com about the prospects for the industry.
NextSWAB is currently optimized for nasal sample collection with validation for other sample types ongoing
Revolutionary ovarian cancer rapid test available Q4 2022
Subscribe To Our Newsletter & Stay Updated
